Related Experiment Video
Updated: May 10, 2026
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets
Maria Adele Mastroianni1, Abid Hussain Llohn, Çiğdem Akalın Akkök
1Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
Abstract:
Reducing the risk of pathogen transmission to transfusion recipients is one of the great concerns in transfusion medicine. Important among the measures suggested to minimise pathogen transmission is pathogen reduction technology (PRT) systems. The present study examined the effects of Mirasol PRT system on MCS+ apheresis platelets in vitro quality measures during a seven-day storage period at 22°C. Statistical analysis indicated no significant difference in platelet concentrations between the control and treated platelet concentrates (PCs) during the storage period. Glucose and lactate levels were measured to determine metabolic activities of control and treated platelets. In both control and treated platelets, the amount of glucose consumed and lactate produced increased significantly with storage time, but glucose consumption and lactate production rates were significantly higher in treated platelets compared with control platelets. The mean pH of treated PCs was decreased at all time points relative to control PCs but remained within acceptable limits. The expression of P-selectin was also higher in Mirasol PRT treated platelets throughout the storage period, but differences were not statistically significant on Days 1 and 4. Finally, visual inspection of swirling indicated that Mirasol PRT treatment of platelets is associated with platelet shape change. Overall, our results show that MCS+ apheresis platelets treated with Mirasol PRT can preserve adequate in vitro properties for at least 5 days of storage.
Insights
Mirasol pathogen reduction technology (PRT) effectively maintains apheresis platelet quality for 5 days. While PRT increases metabolic activity and slightly alters pH, it ensures adequate in vitro properties for transfusion safety.
Area of Science:
- Transfusion Medicine
- Blood Component Processing
- Pathogen Safety
Background:
- Pathogen transmission is a significant risk in transfusion medicine.
- Pathogen Reduction Technology (PRT) systems are crucial for minimizing this risk.
- Evaluating the impact of PRT on platelet concentrate (PC) quality is essential.
Purpose of the Study:
- To assess the in vitro quality of Mirasol PRT-treated apheresis platelets (platelet concentrates) over a 7-day storage period.
- To compare the quality of treated platelets against untreated controls.
- To determine the suitability of Mirasol PRT-treated platelets for clinical use.
Main Methods:
- MCS+ apheresis platelets were treated with the Mirasol PRT system.
- In vitro quality measures, including platelet concentration, glucose, lactate, pH, P-selectin expression, and swirling, were assessed over 7 days at 22°C.
- Statistical analyses were performed to compare control and treated groups.
Main Results:
- Platelet concentration remained comparable between control and treated groups throughout storage.
- Mirasol PRT treatment led to significantly higher glucose consumption and lactate production.
- Treated platelets showed a decrease in pH, remaining within acceptable limits, and increased P-selectin expression, indicating activation.
- Platelet shape change was observed post-treatment.
Conclusions:
- Mirasol PRT-treated apheresis platelets maintain adequate in vitro quality for at least 5 days of storage.
- The observed changes in metabolism, pH, and P-selectin expression require consideration but do not preclude clinical use.
- Mirasol PRT is a viable option for enhancing the safety of platelet transfusions.
More Related Videos
12:40Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024